VIGL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

168.38M

Low

Amount

EV/EBITDA(TTM)

Total Shares

308.72M

EV/OCF(TTM)

P/S(TTM)

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company, which is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, iluzanebart, is a fully human monoclonal antibody agonist targeting the triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The Company is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD).

Events Timeline

(ET)

2025-06-04

07:01:33

Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart

2025-05-21 (ET)

2025-05-21

19:48:02

Vigil Neuroscience to be acquired by Sanofi for $8.00 per share

News

9.0

2025-07-25Benzinga

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

7.0

2025-07-14PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders

7.0

2025-07-03Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR, TASK, VIGL, STRM on Behalf of Shareholders

7.0

2025-06-13Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRKN, ELEV, STR, VIGL on Behalf of Shareholders

7.0

2025-06-13Globenewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTC - CRKN), Elevation Oncology, Inc. (Nasdaq - ELEV), Sitio Royalties Corp. (NYSE - STR), Vigil Neuroscience, Inc. (Nasdaq - VIGL)

7.0

2025-06-09PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

8 Analyst Rating

Wall Street analysts forecast VIGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIGL is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

8 Hold

0 Sell

Hold

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

Current: 0.000

Low

8.00

Averages

8.00

High

8.00

H.C. Wainwright

Buy -> Neutral

downgrade

$14 -> $8

Al Analysis

2025-05-27

Reason

H.C. Wainwright

Price Target

$14 -> $8

Al Analysis

2025-05-27

downgrade

Buy -> Neutral

Reason

H.C. Wainwright downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with a price target of $8, down from $14, after Sanofi (SNY) agreed to acquire Vigil for $470M upfront, with an additional $2 per share contingent on the commercial success of Vigil's Alzheimer's drug, VG-3927, with the deal expected to close in Q3. The firm cites the announced intended acquisition terms for the downgrade.

Stifel

Buy

Hold

downgrade

$11 -> $8

2025-05-27

Reason

Stifel

Price Target

$11 -> $8

2025-05-27

downgrade

Buy

Hold

Reason

Stifel downgraded Vigil Neuroscience (VIGL) to Hold from Buy with a price target of $8, down from $11, following the proposed all-cash transaction by Sanofi (SNY) for $8 per share. Individuals representing 16.2% of Vigil's total common shares outstanding have already signed voting and support agreements in favor of the deal, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VIGL

Unlock Now

Valuation Metrics

The current forward P/E ratio for Vigil Neuroscience Inc (VIGL.O) is -1.15, compared to its 5-year average forward P/E of -2.92. For a more detailed relative valuation and DCF analysis to assess Vigil Neuroscience Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.92

Current PE

-1.15

Overvalued PE

-1.17

Undervalued PE

-4.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.17

Current EV/EBITDA

0.02

Overvalued EV/EBITDA

0.50

Undervalued EV/EBITDA

-2.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.33

Current PS

292.05

Overvalued PS

10.15

Undervalued PS

-9.49

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Vigil Neuroscience Inc (VIGL) stock price today?

The current price of VIGL is 0 USD — it has increased 0 % in the last trading day.

What is Vigil Neuroscience Inc (VIGL)'s business?

What is the price predicton of VIGL Stock?

Wall Street analysts forecast VIGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VIGL is8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Vigil Neuroscience Inc (VIGL)'s revenue for the last quarter?

Vigil Neuroscience Inc revenue for the last quarter amounts to -27.49M USD, increased 22.30 % YoY.

What is Vigil Neuroscience Inc (VIGL)'s earnings per share (EPS) for the last quarter?

Vigil Neuroscience Inc. EPS for the last quarter amounts to -20548000.00 USD, increased 32.51 % YoY.

How many employees does Vigil Neuroscience Inc (VIGL). have?

Vigil Neuroscience Inc (VIGL) has 69 emplpoyees as of January 17 2026.

What is Vigil Neuroscience Inc (VIGL) market cap?

Today VIGL has the market capitalization of 168.38M USD.

VIGL Overview

VIGL Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

People Also Watch

Frequently Asked Questions

What is Vigil Neuroscience Inc (VIGL) stock price today?

What is Vigil Neuroscience Inc (VIGL)'s business?

What is the price predicton of VIGL Stock?

What is Vigil Neuroscience Inc (VIGL)'s revenue for the last quarter?

What is Vigil Neuroscience Inc (VIGL)'s earnings per share (EPS) for the last quarter?

How many employees does Vigil Neuroscience Inc (VIGL). have?

What is Vigil Neuroscience Inc (VIGL) market cap?